How to Invest in Coronavirus Vaccine Stocks
Just follow these three simple steps.
Live: Coronavirus Market Crash Coverage
The Motley Fool’s live guide on what investors should do during the stock market crash and the COVID-19 pandemic.
We’ve created this page for all investors seeking advice on what they should be doing in this turbulent period. Our most important content can be found in the Editors' Picks, section.
We do believe this will all end up behind us, because we view investing as a long-term endeavor. Borrowing from Warren Buffett: "We have no idea -- and never have had -- whether the market is going to go up, down, or sideways in the near- or intermediate-term future." However, we firmly believe investors will be rewarded over the long term.
We suggest bookmarking this page as we will update our Editors' Picks periodically -- the Recent Articles section is a live feed of our latest thinking. Finally, we understand that many people are seeking epidemiological information on COVID-19. For that we strictly suggest visiting the information pages set up by the CDC and WHO.
For members of The Motley Fool's investing services, you can access all our Coronavirus market coverage at fool.com/premium after logging in.
Editors' Picks
3 Coronavirus Stocks That Could Double by the End of 2020
Here's exactly how they could realistically pull it off.
10 Ways COVID-19 Will Affect Social Security
The coronavirus pandemic will have a lasting impact on the nation's most important social program.
What If More Than One Company Wins the Coronavirus Vaccine Race?
The ability to globally distribute a vaccine is as important as the vaccine itself. To the best-equipped victors go the spoils.
Recent articles
Why Novavax Stock Is Jumping Again Today
Investors like that the vaccine maker will soon begin an additional clinical trial targeting the delta variant.
Why Dynavax Stock Is Skyrocketing 45.8% This Week
One of the company's partners launched its COVID-19 vaccine in Taiwan.
3 Top COVID Vaccine Stocks That Wall Street Is Bullish About
Hint: Pfizer, BioNTech, and Moderna didn't make the list.
3 Reasons BioNTech Isn't Nearly as Big as Moderna
Bigger isn't always better.
Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now
The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet.
Why 1 Analyst Predicts Moderna Stock Will Plunge Nearly 70%
The vaccine stock could be priced for even more than perfection.
Why Pfizer and Moderna Won't Make As Much Extra Money From U.S. Booster Doses As You Might Think
There are two simple reasons.
Is Novavax Stock Still a Buy With Its Management's Credibility Crumbling?
The company's executives have repeatedly overpromised and underdelivered.
Is a Meltdown on the Way for Moderna Stock?
There are certainly reasons to think the biotech stock is overpriced right now.
3 Big Hints That COVID Vaccine Booster Doses Are on the Way
The writing could already be on the wall.
Worries About the Delta Variant Could Be Overdone Based on Clues From These Healthcare Giants
What healthcare executives are saying so far about the impact of the coronavirus variant on their businesses is reassuring.
200 Million More Reasons to Buy Pfizer Stock
The giant drugmaker just landed another big supply deal.
Is It Too Late to Buy Novavax Stock?
The answer is in the first two letters of the vaccine maker's name.
How in the World Is Moderna Valued at More Than Half of Pfizer's Market Cap?
There are four possible answers.
Are Booster Doses of Pfizer's and Moderna's COVID Vaccines on the Way?
It's only a maybe for now.
Moderna's Joining the S&P 500: What's Next for the Hot Vaccine Stock?
There's no guarantee that the biotech's share price will continue climbing.
This Stock Should Soar If the Stock Market Crashes This Summer
It's the most likely winner benefiting from the most likely reason that an imminent crash might occur.
3 Things Every Investor Should Know About Pfizer's Dividend
Hint: There's a lot to like.
2 Under-the-Radar Stocks to Buy Now
The stocks have huge upside potential that investors are overlooking.
Why Bionano Genomics, Invitae, and Opko Health Stocks Sank This Week
The market's pessimism about these diagnostics stocks appeared unrelated to company-specific news.